Novo Nordisk’s next-gen obesity drug results a letdown for investors
CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that CagriSema may not be the standout treatment that investors had hoped for. Novo previously reported that patients on CagriSema lost 20% of their weight in a 68-week Phase … [Read more…]